Therefore, our study revealed an RGS19/MYH9/β-catenin/c-Myc regulatory circuit in HCC, supporting RGS19 as a novel diagnostic marker and treatment target in patients with HCC. The gene discussed is RGS19; the disease is hepatocellular carcinoma.